title: Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.
authors.affiliation: Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA. dgranoff@chori.org
authors.forename: Dan M
authors.initials: DM
authors.lastname: Granoff
mesh_terms: D002675:Child, Preschool; D017277:Drug Approval; D005060:Europe; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D014611:Vaccination / Q000379:methods*
chemical_list: C570015:4CMenB vaccine; D022401:Meningococcal Vaccines